Calcitonin (Salmon)
An FDA-approved peptide hormone used to treat osteoporosis and Paget's disease by inhibiting bone resorption.
What is Calcitonin (Salmon)?
Calcitonin is a 32-amino acid peptide hormone naturally produced by the thyroid gland's parafollicular C-cells. Salmon calcitonin is 40-50 times more potent than human calcitonin and is FDA-approved for treatment of postmenopausal osteoporosis and Paget's disease of bone. It works by directly inhibiting osteoclast activity, reducing bone resorption.
What Calcitonin (Salmon) Is Investigated For
Salmon calcitonin is one of the most well-evidenced peptides in this reference, FDA-approved since 1975 for Paget's disease, hypercalcemia of malignancy, and postmenopausal osteoporosis, with decades of clinical data and mechanism that is thoroughly understood at the molecular level. The strongest evidence is for acute hypercalcemia management (rapid calcium-lowering within hours, used as a bridge to bisphosphonate or denosumab effect) and for Paget's disease — indications where calcitonin still has defensible clinical use. For osteoporosis, the PROOF trial did demonstrate vertebral fracture reduction at the 200 IU/day intranasal dose, but the 2012 EMA meta-analysis identified a small but consistent cancer signal in long-term cohorts (0.7-2.4 percentage points absolute risk excess), leading to EMA restrictions and updated FDA labeling in 2013. The consequence is that calcitonin is no longer first-line for chronic osteoporosis — bisphosphonates, denosumab, and anabolic agents all produce larger BMD gains and greater fracture-risk reduction. The honest framing is a genuinely well-evidenced peptide with an uncommonly specific safety signal that has narrowed its clinical niche to short-term and specialty uses.
History & Discovery
Calcitonin was discovered in 1962 by Harold Copp at the University of British Columbia, who identified a then-unknown calcium-lowering hormone produced by the parafollicular C-cells of the thyroid (and originally proposed to come from the parathyroid, hence the name). The hormone was characterized as a 32-amino-acid peptide and quickly recognized as a counter-regulator to parathyroid hormone in calcium homeostasis. The therapeutic insight that salmon calcitonin — produced naturally by ultimobranchial body cells in fish — is roughly 40–50 times more potent than human calcitonin at human calcitonin receptors emerged in the 1960s and led directly to the synthetic salmon calcitonin therapeutic class. Salmon calcitonin (Calcimar, then Miacalcin) received FDA approval in 1975 for parenteral use in Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis. The intranasal spray formulation (Miacalcin Nasal Spray) was approved by the FDA in 1995, dramatically improving patient acceptability and broadening use in postmenopausal osteoporosis. The PROOF trial (Prevent Recurrence of Osteoporotic Fractures) published in 2000 demonstrated a reduction in vertebral fracture incidence at the 200 IU/day intranasal dose but failed to show benefit at lower or higher doses, which contributed to lukewarm guideline endorsement. In 2012, the EMA's Committee for Medicinal Products for Human Use recommended restricting use of calcitonin-containing medicines based on a meta-analysis of 21 trials suggesting a small but consistent increase in cancer risk (approximately 0.7–2.4 percentage points absolute risk increase) with long-term use. The FDA followed with a 2013 advisory panel and labeling changes. Salmon calcitonin nasal spray remains FDA-approved for postmenopausal osteoporosis but is no longer first-line therapy and is positioned as an option only when other agents are not suitable. Use has declined substantially since 2013 in favor of bisphosphonates, denosumab, and the anabolic agents (teriparatide, abaloparatide, romosozumab). Calcitonin retains specific niches: acute hypercalcemia management, Paget's disease, and adjunctive analgesia for acute vertebral compression fractures.
How It Works
Calcitonin tells the cells that break down bone (osteoclasts) to stop working. This slows bone loss and can help relieve pain from bone conditions like osteoporosis and fractures.
Calcitonin binds to the calcitonin receptor (CTR) on osteoclasts, a Class B GPCR that activates cAMP and calcium signaling. This causes rapid osteoclast retraction from bone surfaces, reducing bone resorption. It also has analgesic effects potentially mediated through central serotonergic pathways and beta-endorphin release. Salmon calcitonin's enhanced potency is attributed to its amphipathic alpha-helical structure and resistance to enzymatic degradation.
Evidence Snapshot
Human Clinical Evidence
Extensive. Decades of clinical use with FDA approval. PROOF trial demonstrated vertebral fracture reduction.
Animal / Preclinical
Comprehensive. Calcitonin biology is thoroughly characterized.
Mechanistic Rationale
Very strong. Osteoclast biology and calcitonin receptor signaling are well-understood.
Research Gaps & Open Questions
What the current literature has not yet settled about Calcitonin (Salmon):
- 01Magnitude and mechanism of cancer signal — the EMA meta-analysis identified a small but consistent excess malignancy rate in long-term cohorts; the underlying biological mechanism is incompletely characterized, and patient-selection predictors of risk are not defined.
- 02Place in the modern osteoporosis algorithm — with bisphosphonates, denosumab, and anabolic agents now widely used, the niche for calcitonin in chronic osteoporosis management has narrowed; precise positioning relative to alternatives is more guideline-driven than trial-driven.
- 03Mechanism of analgesic effect — the analgesic action on acute fracture pain appears to be central (potentially via serotonergic and beta-endorphin pathways) rather than peripheral, but the precise mechanism is not fully characterized.
- 04Antibody formation and clinical impact — neutralizing antibodies to salmon calcitonin develop in a meaningful proportion of long-term users; clinical significance and predictors of response loss are incompletely characterized.
- 05Optimal use in acute vertebral compression fracture management — analgesic adjunctive use is supported by some trial data and contradicted by others; meta-analyses are heterogeneous in conclusion.
- 06Calcitonin gene-related peptide (CGRP) crosstalk — the calcitonin family of peptides includes CGRP, amylin, and adrenomedullin with distinct receptor systems; mechanistic crosstalk is incompletely parsed and may be relevant to off-target effects.
Forms & Administration
Nasal spray (Miacalcin/Fortical: 200 IU/day) or subcutaneous/intramuscular injection (100 IU/day). Nasal spray is most common for osteoporosis. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Postmenopausal osteoporosis (intranasal): 200 IU once daily, alternating nostrils. Paget's disease (subcutaneous or intramuscular): 100 IU once daily, with maintenance doses often reduced to 50 IU daily or every other day. Hypercalcemia (subcutaneous or intramuscular): 4 IU/kg every 12 hours, increased to 8 IU/kg every 12 hours and then every 6 hours if response is inadequate.
Frequency
Intranasal: once daily for chronic osteoporosis treatment, with alternating nostrils to minimize local irritation. Parenteral: daily or every-12-hours for hypercalcemia (typically a short hospital-based course), daily or alternate-day for Paget's disease maintenance.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
For osteoporosis, calcitonin is no longer recommended for long-term continuous use given the cancer signal — when used at all, it is typically a short-to-intermediate course or reserved for patients unable to tolerate other therapies. Acute hypercalcemia treatment is days, not chronic. Paget's disease maintenance can be longer but is typically transitioned to bisphosphonate therapy.
Protocol Notes
Intranasal administration is straightforward but requires patient training on activation and proper technique; the spray loses potency once activated and must be used promptly. Refrigeration is required for unopened bottles; once activated, the spray is stable at room temperature for approximately 35 days. Local nasal irritation, dryness, and minor bleeding are common with the intranasal form and are reduced by alternating nostrils with each dose. For Paget's disease, bisphosphonates (zoledronic acid in particular) have largely supplanted calcitonin as first-line therapy because of superior alkaline phosphatase suppression and longer remission. Calcitonin retains a role for patients who cannot tolerate bisphosphonates or in whom rapid analgesic effect on Paget's bone pain is needed. In acute hypercalcemia, calcitonin works rapidly (hours) and provides early control while waiting for bisphosphonate or denosumab effect (which takes 24–72 hours). Tachyphylaxis develops within 24–48 hours, limiting its standalone use; it is essentially a bridging agent. Calcitonin's analgesic effect on acute vertebral compression fracture pain — distinct from its bone-remodeling effect — has been used adjunctively though evidence is mixed. Antibody formation against salmon calcitonin develops in a meaningful proportion of long-term users and can attenuate response over time, contributing to the diminishing utility for chronic osteoporosis management.
Salmon calcitonin nasal spray is FDA-approved for postmenopausal osteoporosis but is not first-line therapy following the 2013 cancer-risk labeling changes. It is one option among many and should be selected only when other agents (bisphosphonates, denosumab, anabolic agents) are unsuitable.
Timeline of Effects
Onset
Subcutaneous calcitonin produces detectable effects on serum calcium within hours; in acute hypercalcemia management, meaningful calcium reduction is observed within 4–6 hours. Intranasal calcitonin produces measurable bone-resorption marker (CTX) suppression within days of initiation. Analgesic effect on acute vertebral fracture pain is reported within 1–2 weeks for those who respond.
Peak Effect
For chronic osteoporosis, BMD changes with intranasal calcitonin are modest — typically 1–2% gains at the lumbar spine over 1–2 years, substantially less than bisphosphonates or anabolic agents. The PROOF trial vertebral fracture reduction was demonstrated at 5 years of treatment. For acute hypercalcemia, peak calcium-lowering effect is within 24 hours of initiating therapy.
After Discontinuation
Acute hypercalcemic effect dissipates within 24–48 hours of stopping (and tachyphylaxis develops with continuous use anyway). For chronic osteoporosis use, BMD gains attenuate after discontinuation but the magnitude of loss is less dramatic than with teriparatide because the underlying gains were modest to begin with. There is no rebound phenomenon. Antibodies that develop with chronic use may persist for months after stopping.
Common Questions
Who Calcitonin (Salmon) Is NOT For
- •Known hypersensitivity to salmon calcitonin or to any formulation excipient — anaphylactic and serious hypersensitivity reactions have been reported, including in patients without prior exposure.
- •Pregnancy and breastfeeding — limited safety data; not recommended outside clinical necessity.
- •Pre-existing hypocalcemia — would be worsened by calcitonin.
- •History of malignancy where prolonged use would expose the patient to additional risk — given the small but documented cancer signal in long-term cohorts, prolonged use in patients with prior cancer history warrants careful risk-benefit discussion.
- •Children and pediatric use — not established for chronic use; safety in pediatric populations is not adequately characterized.
- •Significant nasal pathology that would compromise intranasal absorption (severe rhinitis, recent nasal surgery, septal perforation) — switch to parenteral form or alternative agent.
Drug & Supplement Interactions
Salmon calcitonin has a relatively limited drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. The clinically important interactions are pharmacodynamic. Lithium: calcitonin can decrease serum lithium concentration, potentially leading to subtherapeutic levels in patients with bipolar disorder or other lithium-dependent indications. Lithium dose adjustment and serum-level monitoring may be required during initiation or discontinuation of calcitonin therapy. Bisphosphonates and denosumab: combining calcitonin with other antiresorptive agents has not been shown to provide additional benefit and is not standard practice. Sequential rather than concurrent use is the norm. Vitamin D and calcium supplementation: routinely given alongside calcitonin for osteoporosis or Paget's disease as supportive care; clinically synergistic rather than interacting in a problematic sense. Loop diuretics that affect calcium handling and other agents that modulate calcium balance should be monitored when used concurrently. As with any chronic specialty therapy, all medications including OTC supplements should be disclosed to the prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • FDA warning about potential cancer risk with long-term use
- • Not first-line therapy for osteoporosis anymore
- • Antibody formation may reduce efficacy over time
What We Don't Know
Long-term cancer risk concerns have limited its use, though the absolute risk increase appears small.
Legal Status
United States
Salmon calcitonin (Miacalcin, Fortical, multiple generics) is FDA-approved for postmenopausal osteoporosis (intranasal spray, 200 IU/day), Paget's disease of bone, and hypercalcemia of malignancy. The FDA reviewed cancer-risk data in 2013 and updated labeling to recommend use only when alternatives are not suitable; specifically for postmenopausal osteoporosis the labeling notes the small absolute increase in malignancy risk seen in long-term users. Generic salmon calcitonin nasal spray is widely available. It is a prescription-only medication, not a controlled substance.
International
Approved across major markets historically. The EMA's 2012 review led to restrictions across the EU: intranasal salmon calcitonin is no longer approved for postmenopausal osteoporosis in the EU and is restricted to short-term use (up to 4 weeks) for prevention of acute bone loss due to sudden immobilization, Paget's disease in patients unresponsive to alternatives, and hypercalcemia of malignancy. UK MHRA position is similar. Approval and labeling vary by jurisdiction; the US labeling is less restrictive than the EU position.
Sports & Competition
Calcitonin is not specifically named on the WADA Prohibited List. It does not have meaningful performance-enhancing pharmacology in athletes with normal bone metabolism. Therapeutic use under appropriate documentation is generally not problematic.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Calcitonin is a first-line treatment for osteoporosis.
Reality
It is no longer considered first-line. Bisphosphonates, denosumab, and anabolic agents (teriparatide, abaloparatide, romosozumab) all produce larger BMD gains and greater fracture-risk reduction than calcitonin. Following the 2013 FDA labeling changes (and EMA restrictions in 2012), calcitonin is positioned as an option only when other agents are not suitable.
Myth
Salmon calcitonin and human calcitonin are equivalent.
Reality
Salmon calcitonin is approximately 40–50 times more potent than human calcitonin at the human calcitonin receptor due to structural differences (greater amphipathic alpha-helix stability, increased receptor affinity). It is also more resistant to enzymatic degradation. Human calcitonin (calcitonin-Cibacalcin, no longer marketed in the US) was largely replaced by salmon calcitonin for these reasons.
Myth
The cancer signal with calcitonin is large enough to make it dangerous.
Reality
The signal identified in the 2012 EMA meta-analysis is small in absolute terms (approximately 0.7–2.4 percentage points absolute risk excess in long-term users). Whether the signal is causal or confounded remains debated. The significance of this small signal in the context of effective alternatives is what shifted calcitonin out of first-line use; in patients without alternatives, calcitonin remains an option with appropriate informed consent.
Myth
Intranasal calcitonin is more effective than injection because the dose is higher.
Reality
The 200 IU intranasal dose was chosen to compensate for lower bioavailability through nasal mucosa (estimated 3–25%), bringing systemic exposure roughly equivalent to lower-dose parenteral administration. The intranasal route is preferred for chronic use because of patient acceptability, not because it is more potent.
Myth
Calcitonin can replace teriparatide for severe osteoporosis.
Reality
It cannot. Calcitonin is antiresorptive (slows bone breakdown) with modest effect; teriparatide is anabolic (stimulates new bone formation) with substantially larger BMD gains. The two agents serve different roles in the osteoporosis algorithm and are not interchangeable for severe high-fracture-risk disease.
Published Research
12 studiesRevisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management
High-throughput method for Peptide mapping and Amino acid sequencing for Calcitonin Salmon in Calcitonin Salmon injection using Ultra High Performance Liquid Chromatography - High Resolution Mass Spectrometry (UHPLC-HRMS) with the application of Bioinformatic tools
Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry
Can calcitonin nasal spray reduce the risk of recurrence of central giant cell granuloma of the jaws? A double-blind clinical trial
Experts recommend against calcitonin-salmon for postmenopausal osteoporosis
Development of Calcitonin Salmon Nasal Spray: similarity of peptide formulated in chlorobutanol compared to benzalkonium chloride as preservative
Calcitonin for osteoporosis and bone pain
Stability of calcitonin salmon in nasal spray at elevated temperatures
Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study
Comparative effects of eel calcitonin, salmon calcitonin and [Asu1,7]eel calcitonin on hypophyseal and osteoblastic function
Quick Facts
- Class
- Peptide Hormone
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- May 2026
- Citations
- 12PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.